Literature DB >> 10448425

The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease.

C D Hardman1, G M Halliday.   

Abstract

Our structural studies of the substantia nigra in parkinsonian patients identified previously unsuspected changes in the pars reticulata, suggesting significant dysfunction in this basal ganglia output. There have been few similar structural studies of the other major basal ganglia output, the internal segment of the globus pallidus. This is despite significant evidence that this basal ganglia region is crucially important for generating parkinsonian symptoms. In fact current surgical interventions target this region in Parkinson's disease. The cellular anatomy of the internal globus pallidus was compared among five controls, six patients with Parkinson's disease, and five patients with progressive supranuclear palsy. Neurons and pathological structures were quantified using the unbiased fractionator method. Only cases with progressive supranuclear palsy had detectable pathology within the internal globus pallidus in the form of tau-positive neuronal and glial tangles and substantial neurodegeneration. Cases with Parkinson's disease had a significant reduction in the proportion of neurons containing parvalbumin but were without significant neurodegeneration, consistent with dysfunction of both basal ganglia output nuclei in advanced parkinsonism. Surgical ablation of the internal globus pallidus for Parkinson's disease appears at odds with the significant neurodegeneration in the similarly akinetic and rigid patients with progressive supranuclear palsy. The results are discussed in association with current hypotheses of basal ganglia function and recent experimentation in patients undergoing pallidotomy for hyperkinetic disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448425     DOI: 10.1006/exnr.1999.7072

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

2.  The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases.

Authors:  N M Warren; M A Piggott; A J Lees; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

3.  An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.

Authors:  Natalie Connor-Robson; Heather Booth; Jeffrey G Martin; Benbo Gao; Kejie Li; Natalie Doig; Jane Vowles; Cathy Browne; Laura Klinger; Peter Juhasz; Christine Klein; Sally A Cowley; Paul Bolam; Warren Hirst; Richard Wade-Martins
Journal:  Neurobiol Dis       Date:  2019-04-05       Impact factor: 5.996

4.  Gray Matter Atrophy in Parkinson's Disease and the Parkinsonian Variant of Multiple System Atrophy: A Combined ROI- and Voxel-Based Morphometric Study.

Authors:  Xiaorui Cui; Lan Li; Lei Yu; Huijuan Xing; Hong Chang; Li Zhao; Jin Qian; Qingwei Song; Shiyu Zhou; Chunbo Dong
Journal:  Clinics (Sao Paulo)       Date:  2020-06-12       Impact factor: 2.365

5.  Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.

Authors:  Marc Morissette; Mélanie Bourque; Marie-Ève Tremblay; Thérèse Di Paolo
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

6.  Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: Report of three cases.

Authors:  Domenico Servello; Edvin Zekaj; Christian Saleh; Claudia Menghetti; Mauro Porta
Journal:  Surg Neurol Int       Date:  2014-09-05

7.  iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases.

Authors:  Ethan W Hollingsworth; Jacob E Vaughn; Josh C Orack; Chelsea Skinner; Jamil Khouri; Sofia B Lizarraga; Mark E Hester; Fumihiro Watanabe; Kenneth S Kosik; Jaime Imitola
Journal:  EMBO Mol Med       Date:  2017-12       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.